BRISTOL-MYERS SQUIBB TOP R&D POSITION WILL BE HELD BY EDGAR HABER, MD
BRISTOL-MYERS SQUIBB TOP R&D POSITION WILL BE HELD BY EDGAR HABER, MD, who will hold the title of president of Bristol-Myers Squibb Pharmaceutical Research Institute. His responsibilities will include Bristol-Myers Pharmaceutical R&D Division, Oncogen, and Squibb Institute for Medical Research, Bristol-Myers Squibb announced March 20. Haber had been head of the Squibb Institute for Medical Research since January 1988. Prior to joining Squibb, Haber was chief of cardiology at Mass General for 24 years. Haber had also been a professor at Harvard Medical School. Haber will report directly to his boss at Squibb -- Bristol-Myers Squibb President Richard Furlaud. William Comer, PhD, who had headed the Bristol-Myers Pharmaceutical R&D Division, has been appointed to Bristol-Myers Squibb senior VP-strategic management, reporting to Wayne Davidson, president of Bristol-Myers Squibb Pharmaceutical and Nutritional Group, the company announced March 21. Although Comer apparently headed Bristol-Myers R&D in 1989, the company announced that appointment in December ("The Pink Sheet" Jan. 1, 1990, "In Brief"), several months after the merger was finalized. * In addition, the company said that the still separate pharmaceutical R&D functions "within the operating units of the Bristol-Myers Squibb Pharmaceutical Research Institute will be integrated more completely during the second quarter of this year." Bristol-Myers Squibb also announced the formation of an operating committee of the company's pharmaceutical research institute. The committee will include: Stephen Carter, MD, who replaces Comer as president of Bristol-Myers Pharmaceutical Research and Development Division and will be responsible for worldwide clinical development; George Todaro, MD, president of Oncogen, who will also assume responsibilities for exploratory pharmaceutical research; Andrew Bodnar, MD/JD, senior VP and chief operating officer of the Squibb Institute, who will be responsible for administrative and planning functions; Kenneth Given, MD, senior VP-worldwide medical and regulatory affairs at the Squibb Institute, who will be responsible for worldwide regulatory affairs; and William Scott, PhD, senior VP-molecular and cellular biology at the Squibb Institute, responsible for drug discovery.
Sign in to continue reading.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: